2026. Sensitivity of KRAS-Mutated Non-Small Cell Lung Cancer to a Combination of MEK Kinase Inhibitor (Trametinib) and Autophagy Inhibitor (Hydroxychloroquine) in a Tissue Explant Model. Voprosy onkologii. 72, 1 (Mar. 2026), OF-2403. DOI:https://doi.org/10.37469/0507-3758-2026-72-1-OF-2403.